David Hirsch, MD, PhD
Dr. Hirsch is currently Chief Executive Officer of Alpha-9 Theranostics Inc., a clinical stage radiopharmaceutical company, and a Venture Partner of Longitude Capital, a healthcare venture capital firm.
Dr. Hirsch co-founded Longitude Capital in 2006, where he served as a Managing Director until 2022. Prior to Longitude Capital, Dr. Hirsch was a Vice President of Pequot Ventures, where he worked in the life sciences practice. Prior to Pequot Ventures, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. Dr. Hirsch currently serves on the board of directors of Molecular Templates, Inc. (MTEM) and Tricida, Inc. (TCDA). Dr Hirsch previously served on the board of directors of multiple other companies in the life sciences industry, including Collegium Pharmaceutical, Inc. (COLL) and Poseida Therapeutics, Inc. (PSTX). Dr. Hirsch holds a Ph.D. in Biology from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a B.A. in Biology from Johns Hopkins University.